The Alpha-Synuclein Propagation Models debate represents a central controversy in Parkinson's disease (PD) and related synucleinopathies. This debate centers on the mechanisms by which pathological alpha-synuclein (α-syn) spreads through the nervous system and from cell to cell. Understanding these propagation mechanisms is critical for developing disease-modifying therapies that can halt or slow disease progression. [1]
The Prion-Like Model proposes that pathological α-syn acts as a self-propagating template that induces misfolding of endogenous normal α-syn in recipient cells 1. [2]
Key Features: [3]
Supporting Evidence: [4]
The Tunneling Nanotube (TNT) Model suggests that α-syn spreads through direct cytoplasmic connections between cells 5. [5]
Key Features: [6]
Supporting Evidence: [7]
The Extracellular Vesicle Model proposes that α-syn propagates via exosomes and other extracellular vesicles 7. [8]
Key Features: [9]
Supporting Evidence:
The Activity-Dependent Model suggests that neuronal activity influences α-syn propagation, with more active neurons being preferential recipients or transmitters 9.
Key Features:
Supporting Evidence:
| Evidence Type | Supports Prion-Like | Supports TNTs | Supports Exosomes | Supports Activity-Dependent |
|---|---|---|---|---|
| In vivo seeding | Strong | Weak | Moderate | Moderate |
| Cell culture | Strong | Moderate | Strong | Moderate |
| Patient samples | Strong | Limited | Strong | Moderate |
| Therapeutic implications | Immunotherapy | Cell junction targets | Vesicle blockade | Activity modulation |
The field is moving toward an integrated model where multiple propagation mechanisms likely operate simultaneously:
| Model | Therapeutic Target | Approach |
|---|---|---|
| Prion-Like | Seeds/Oligomers | Immunotherapy, aggregation inhibitors |
| TNTs | Cell junctions | Anti-inflammatory, junction stabilizers |
| Exosomes | Vesicle release/release | Tetraspanin inhibitors, fusion blockers |
| Activity-Dependent | Neuronal activity | Activity modulators, deep brain stimulation |
Braak H, Del Tredici K, Rüb U, et al. [ Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003](https://doi.org/10.1016/s0197-4580(02). 2003. ↩︎
Luk KC, Kehm V, Zhang J, et al. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med. 2012. 2012. ↩︎
Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2016. 2016. ↩︎
Guo JL, Covell DJ, Daniels JP, et al. Distinct alpha-synuclein strains differentially accelerate tau inclusion formation. Cell. 2013. 2013. ↩︎
Wang X, Wang K, Wang L, et al. Tunneling Nanotubes in Neurodegeneration. Trends Neurosci. 2019. 2019. ↩︎
Abounit S, Bousset L, Loria F, et al. Tunneling nanotubes spread fibrillar alpha-synuclein between cells. Neurosci Lett. 2016. 2016. ↩︎
Stuendl A, Kunadt M, Kramer K, et al. Induction of alpha-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies. Brain. 2016. 2016. ↩︎
Shi M, Liu C, Cook TJ, et al. Plasma exosomal alpha-synuclein is likely CNS-derived and increased in Parkinson's disease. Acta Neuropathol. 2014. 2014. ↩︎
Chen Y, Yang W, Li X, et al. Neuronal activity promotes alpha-synuclein aggregation via exosome release. Nat Neurosci. 2023. 2023. ↩︎